Company intelligence / Profile preview

TheraVectys

Ownership: Private
Employees: ~11
Development stage: Preclinical

Overview

TheraVectys has developed a proprietary lentiviral vector immunotherapy platform that induces strong and durable T cell and antibody responses. The company’s lead programs target cancer and major infectious diseases. At least one therapeutic vaccine for Adult T-cell Leukemia/Lymphoma has advanced through preclinical optimization toward Phase I/II trials. Additional oncology programs were planned for early-phase clinical studies as of the last available updates.

Therapeutic areas: OncologyInfectious Diseases
Modalities: VaccineGene therapy (Lentiviral vector-based)Cell therapy (T-cell therapies)
Industry: Biotech

Drug pipeline

21 assets

Lenti-HPV-07

20 more assets in the full pipeline.

Partnerships

Institut Pasteur – exclusive global licensing agreement on lentiviral vectors for vaccine applications; joint laboratory established with Institut Pasteur in Paris.

Beyond the preview

Go deeper on TheraVectys.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TheraVectys.